Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b observational study of JAK2V617F allele burden reduction in polycythemia vera
jRCT1071240115Recruiting
- Sponsor
- PharmaEssentia
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by PharmaEssentia. Primary endpoint: Achievement rate of JAK2V617F allele burden <10%. Started Mar 2025; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on jRCT1071240115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071240115.